M
Michael J. Mack
Researcher at Scott & White Hospital
Publications - 634
Citations - 36680
Michael J. Mack is an academic researcher from Scott & White Hospital. The author has contributed to research in topics: Valve replacement & Medicine. The author has an hindex of 89, co-authored 519 publications receiving 28877 citations. Previous affiliations of Michael J. Mack include Baylor University Medical Center & Medical City Dallas Hospital.
Papers
More filters
Journal ArticleDOI
Transcatheter Mitral-Valve Repair in Patients with Heart Failure.
Gregg W. Stone,JoAnn Lindenfeld,William T. Abraham,Saibal Kar,D. Scott Lim,Jacob M. Mishell,Brian Whisenant,Paul A. Grayburn,Michael Rinaldi,Samir R. Kapadia,Vivek Rajagopal,Ian J. Sarembock,Andreas Brieke,Steven O. Marx,David J. Cohen,Neil J. Weissman,Michael J. Mack +16 more
TL;DR: Among patients with heart failure and moderate‐to‐severe or severe secondary mitral regurgitation who remained symptomatic despite the use of maximal doses of guideline‐directed medical therapy, transcatheter mitral‐valve repair resulted in a lower rate of hospitalization forHeart failure and lower all‐cause mortality within 24 months of follow‐up than medical therapy alone.
Journal ArticleDOI
Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease : 5-year follow-up of the randomised, clinical SYNTAX trial
Friedrich W. Mohr,Marie Claude Morice,A. Pieter Kappetein,Ted Feldman,Elisabeth Ståhle,Antonio Colombo,Michael J. Mack,David R. Holmes,Marie Angèle Morel,Nic Van Dyck,Vicki M. Houle,Keith D. Dawkins,Patrick W. Serruys +12 more
TL;DR: CABG should remain the standard of care for patients with complex lesions (high or intermediate SYNTAX scores) or left main coronary disease (low or intermediateSYNTAx scores), PCI is an acceptable alternative.
Journal ArticleDOI
Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis
Vinod H. Thourani,Susheel Kodali,Raj Makkar,Howard C. Herrmann,Mathew R. Williams,Vasilis Babaliaros,Richard W. Smalling,Scott Lim,S. Chris Malaisrie,Samir R. Kapadia,Wilson Y. Szeto,Kevin L. Greason,Dean J. Kereiakes,Gorav Ailawadi,Brian Whisenant,Chandan Devireddy,Jonathon Leipsic,Rebecca T. Hahn,Philippe Pibarot,Neil J. Weissman,Wael A. Jaber,David J. Cohen,Rakesh M. Suri,E. Murat Tuzcu,Lars G. Svensson,John G. Webb,Jeffrey W. Moses,Michael J. Mack,D. Craig Miller,Craig R. Smith,Maria Alu,Rupa Parvataneni,Ralph B. D'Agostino,Martin B. Leon +33 more
TL;DR: TAVR with SAPIEN 3 in intermediate-risk patients with severe aortic stenosis is associated with low mortality, strokes, and regurgitation at 1 year after implantation, and a significant superiority for the composite outcome with TAVR compared with surgery is indicated.
Journal ArticleDOI
Frailty Assessment in the Cardiovascular Care of Older Adults
Jonathan Afilalo,Karen P. Alexander,Michael J. Mack,Mathew S. Maurer,Philip Green,Larry A. Allen,Jeffrey J. Popma,Luigi Ferrucci,Daniel E. Forman +8 more
TL;DR: This work sought to synthesize the existing body of evidence and offer a perspective on how to integrate frailty into clinical practice and contribute valuable prognostic insights incremental to existing risk models and assists clinicians in defining optimal care pathways for their patients.
Journal ArticleDOI
5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial
Samir R. Kapadia,Martin B. Leon,Raj Makkar,E. Murat Tuzcu,Lars G. Svensson,Susheel Kodali,John G. Webb,Michael J. Mack,Pamela S. Douglas,Vinod H. Thourani,Vasilis Babaliaros,Howard C. Herrmann,Wilson Y. Szeto,Augusto D. Pichard,Mathew R. Williams,Gregory P. Fontana,D. Craig Miller,William N. Anderson,Craig R. Smith,Jodi J. Akin,Michael J. Davidson +20 more
TL;DR: TAVR should be strongly considered for patients who are not surgical candidates for aortic valve replacement to improve their survival and functional status, and Appropriate selection of patients will help to maximise the benefit of TAVR and reduce mortality from severe comorbidities.